Literature DB >> 25157104

Nuclear matrix protein SMAR1 represses c-Fos-mediated HPV18 E6 transcription through alteration of chromatin histone deacetylation.

Samik Chakraborty1, Kaushik Das1, Shilpi Saha1, Minakshi Mazumdar1, Argha Manna1, Sreeparna Chakraborty1, Shravanti Mukherjee1, Poulami Khan1, Arghya Adhikary1, Suchismita Mohanty1, Samit Chattopadhyay2, Subhash C Biswas3, Gaurisankar Sa1, Tanya Das4.   

Abstract

Matrix attachment region (MAR)-binding proteins have been implicated in the transcriptional regulation of host as well as viral genes, but their precise role in HPV-infected cervical cancer remains unclear. Here we show that HPV18 promoter contains consensus MAR element in the LCR and E6 sequences where SMAR1 binds and reinforces HPV18 E6 transcriptional silencing. In fact, curcumin-induced up-regulation of SMAR1 ensures recruitment of SMAR1-HDAC1 repressor complex at the LCR and E6 MAR sequences, thereby decreasing histone acetylation at H3K9 and H3K18, leading to reorientation of the chromatin. As a consequence, c-Fos binding at the putative AP-1 sites on E6 promoter is inhibited. E6 depletion interrupts degradation of E6-mediated p53 and lysine acetyl transferase, Tip60. Tip60, in turn, acetylates p53, thereby restoring p53-mediated transactivation of proapoptotic genes to ensure apoptosis. This hitherto unexplained function of SMAR1 signifies the potential of this unique scaffold matrix-associated region-binding protein as a critical regulator of E6-mediated anti-apoptotic network in HPV18-infected cervical adenocarcinoma. These results also justify the candidature of curcumin for the treatment of HPV18-infected cervical carcinoma.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Cancer Prevention; FBJ Murine Osteosarcoma Viral Oncogene Homolog (Fos); Histone Deacetylase (HDAC); Papillomavirus; Transcription Repressor

Mesh:

Substances:

Year:  2014        PMID: 25157104      PMCID: PMC4200262          DOI: 10.1074/jbc.M114.564872

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  HIV-1 integration sites are flanked by potential MARs that alone can act as promoters.

Authors:  Asavari Kulkarni; L Pavithra; Shravanti Rampalli; Devraj Mogare; Kumar Babu; Gazalla Shiekh; Susmita Ghosh; Samit Chattopadhyay
Journal:  Biochem Biophys Res Commun       Date:  2004-09-17       Impact factor: 3.575

2.  Epidemiology of adenocarcinoma of the cervix.

Authors:  F Parazzini; C La Vecchia
Journal:  Gynecol Oncol       Date:  1990-10       Impact factor: 5.482

3.  Nuclear matrix attachment regions of human papillomavirus type 16 repress or activate the E6 promoter, depending on the physical state of the viral DNA.

Authors:  W Stünkel; Z Huang; S H Tan; M J O'Connor; H U Bernard
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

4.  p53, retinoblastoma gene product, and cyclin protein expression in human papillomavirus virus DNA-positive cervical intraepithelial neoplasia and invasive cancer.

Authors:  A J Amortegui; M P Meyer; V L Elborne; R M Amin
Journal:  Mod Pathol       Date:  1995-12       Impact factor: 7.842

5.  Human papillomavirus DNA in adenocarcinoma and adenosquamous carcinoma of the uterine cervix detected by polymerase chain reaction (PCR).

Authors:  Y Yamakawa; O Forslund; H Teshima; K Hasumi; T Kitagawa; B G Hansson
Journal:  Gynecol Oncol       Date:  1994-05       Impact factor: 5.482

6.  Direct interaction with and activation of p53 by SMAR1 retards cell-cycle progression at G2/M phase and delays tumor growth in mice.

Authors:  Ruchika Kaul; Sujoy Mukherjee; Farid Ahmed; Manoj Kumar Bhat; Rishiraj Chhipa; Sanjeev Galande; Samit Chattopadhyay
Journal:  Int J Cancer       Date:  2003-02-20       Impact factor: 7.396

7.  Telomerase activation by the E6 gene product of human papillomavirus type 16.

Authors:  A J Klingelhutz; S A Foster; J K McDougall
Journal:  Nature       Date:  1996-03-07       Impact factor: 49.962

Review 8.  Human papillomavirus and cervical cancer.

Authors:  Eileen M Burd
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

9.  Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3.

Authors:  Xiaohong Zhang; Walker Wharton; Zhigang Yuan; Shih-Chang Tsai; Nancy Olashaw; Edward Seto
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

10.  ROS-PIASγ cross talk channelizes ATM signaling from resistance to apoptosis during chemosensitization of resistant tumors.

Authors:  S Mohanty; S Saha; D Md S Hossain; A Adhikary; S Mukherjee; A Manna; S Chakraborty; M Mazumdar; P Ray; K Das; J Chakraborty; G Sa; T Das
Journal:  Cell Death Dis       Date:  2014-01-23       Impact factor: 8.469

View more
  10 in total

Review 1.  Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors.

Authors:  Eunah Kim; William H Bisson; Christiane V Löhr; David E Williams; Emily Ho; Roderick H Dashwood; Praveen Rajendran
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

2.  Vorinostat, a pan-HDAC inhibitor, abrogates productive HPV-18 DNA amplification.

Authors:  N Sanjib Banerjee; Dianne W Moore; Thomas R Broker; Louise T Chow
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-01       Impact factor: 11.205

Review 3.  A model for the control of DNA integrity by the sperm nuclear matrix.

Authors:  Joanna E Gawecka; Jordi Ribas-Maynou; Jordi Benet; W Steven Ward
Journal:  Asian J Androl       Date:  2015 Jul-Aug       Impact factor: 3.285

4.  Morphoproteomics, E6/E7 in-situ hybridization, and biomedical analytics define the etiopathogenesis of HPV-associated oropharyngeal carcinoma and provide targeted therapeutic options.

Authors:  Robert E Brown; Syed Naqvi; Mary F McGuire; Jamie Buryanek; Ron J Karni
Journal:  J Otolaryngol Head Neck Surg       Date:  2017-08-17

5.  Aspirin enhances cisplatin sensitivity of resistant non-small cell lung carcinoma stem-like cells by targeting mTOR-Akt axis to repress migration.

Authors:  Poulami Khan; Apoorva Bhattacharya; Debomita Sengupta; Shruti Banerjee; Arghya Adhikary; Tanya Das
Journal:  Sci Rep       Date:  2019-11-15       Impact factor: 4.379

Review 6.  Pathogen-Induced Epigenetic Modifications in Cancers: Implications for Prevention, Detection and Treatment of Cancers in Africa.

Authors:  Alexandra Lindsey Djomkam Zune; Charles Ochieng' Olwal; Kesego Tapela; Oloche Owoicho; Nora Nghochuzie Nganyewo; Frank Lyko; Lily Paemka
Journal:  Cancers (Basel)       Date:  2021-12-01       Impact factor: 6.639

Review 7.  Dietary supplements for treatment of endometriosis: A review.

Authors:  Pınar Yalçın Bahat; Işıl Ayhan; Eda Üreyen Özdemir; Ümit İnceboz; Engin Oral
Journal:  Acta Biomed       Date:  2022-03-14

8.  Tumor Restrictive Suicide Gene Therapy for Glioma Controlled by the FOS Promoter.

Authors:  Jianqing Pan; Hao Wang; Xinmin Liu; Jiliang Hu; Weijian Song; Jie Luo; Shan Jiang; Fei Yan; Baojin Zhai
Journal:  PLoS One       Date:  2015-11-16       Impact factor: 3.240

9.  Genome-wide association study of copy number variation with lung function identifies a novel signal of association near BANP for forced vital capacity.

Authors:  Nick Shrine; Martin D Tobin; Claudia Schurmann; María Soler Artigas; Jennie Hui; Terho Lehtimäki; Olli T Raitakari; Craig E Pennell; Qi Wei Ang; David P Strachan; Georg Homuth; Sven Gläser; Stephan B Felix; David M Evans; John Henderson; Raquel Granell; Lyle J Palmer; Jennifer Huffman; Caroline Hayward; Generation Scotland; Anders Malarstig; Bill Musk; Alan L James; Louise V Wain
Journal:  BMC Genet       Date:  2016-08-11       Impact factor: 2.797

10.  Aspirin inhibits epithelial-to-mesenchymal transition and migration of oncogenic K-ras-expressing non-small cell lung carcinoma cells by down-regulating E-cadherin repressor Slug.

Authors:  Poulami Khan; Argha Manna; Shilpi Saha; Suchismita Mohanty; Shravanti Mukherjee; Minakshi Mazumdar; Deblina Guha; Tanya Das
Journal:  BMC Cancer       Date:  2016-01-26       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.